Mahmud Omar, Fatimi Asad Saulat, Grewal Mahip, DiMaggio Charles, Hewitt D Brock, Javed Ammar A, Wolfgang Christopher L, Sacks Greg D
Medical College, Aga Khan University, Karachi, Pakistan; NYU Langone Health, NYU Grossman School of Medicine, New York City, USA.
NYU Langone Health, NYU Grossman School of Medicine, New York City, USA.
Eur J Surg Oncol. 2025 Jul;51(7):109742. doi: 10.1016/j.ejso.2025.109742. Epub 2025 Mar 5.
Current guidelines recommend the resection of main duct- (MD) and mixed-type (MT) intraductal papillary mucinous neoplasms (IPMN) based on specific risk criteria to prevent or treat pancreatic cancer in selected patients. This paradigm follows high rates of malignancy observed in published surgical series. The aim of this systematic review and meta-analysis was to provide robust, pooled rates of invasive carcinoma (IC) and high-grade dysplasia (HGD) in resected MD- and MT-IPMNs of the pancreas.
The PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL databases were systematically searched. Studies that reported rates of IC or HGD, diagnosed by histopathology of surgical specimens, in MD- or MT-IPMNs were included. Pooled prevalence with 95 % confidence interval (95 % CI) was calculated using a random effects model. Galbraith plots were used to evaluate heterogeneity. Risk of bias was assessed using the National Institutes of Health Quality Assessment Tool.
Based on 51 studies, 59 % (95 % CI: 54 %, 64 %) of resected MD- and MT-IPMN had IC or HGD, with IC in up to 39 % (95 % CI: 33 %, 44 %) of lesions and HGD in 20 % (95 % CI: 16 %, 25 %). Most studies were deemed to be of good quality and Galbraith plots demonstrated high concordance.
These results confirm the rates of IC and HGD in resected MD/MT-IPMNs. However, a significant proportion of patients have benign lesions, and future research is needed to develop precise diagnostics to distinguish between patients with and without high-risk or cancerous disease.
当前指南建议根据特定风险标准切除主胰管型(MD)和混合型(MT)导管内乳头状黏液性肿瘤(IPMN),以预防或治疗特定患者的胰腺癌。这一模式是基于已发表的手术系列研究中观察到的高恶性率。本系统评价和荟萃分析的目的是提供胰腺切除的MD-和MT-IPMN中浸润性癌(IC)和高级别异型增生(HGD)的可靠合并发生率。
系统检索PubMed、Embase、Scopus、Web of Science和Cochrane CENTRAL数据库。纳入报告通过手术标本组织病理学诊断的MD-或MT-IPMN中IC或HGD发生率的研究。使用随机效应模型计算合并患病率及95%置信区间(95%CI)。使用Galbraith图评估异质性。使用美国国立卫生研究院质量评估工具评估偏倚风险。
基于51项研究,59%(95%CI:54%,64%)的切除MD-和MT-IPMN有IC或HGD,其中IC高达39%(95%CI:33%,44%)的病变,HGD为20%(95%CI:16%,25%)。大多数研究被认为质量良好,Galbraith图显示高度一致性。
这些结果证实了切除的MD/MT-IPMN中IC和HGD的发生率。然而,相当一部分患者有良性病变,未来需要开展研究以开发精确诊断方法,区分有和没有高危或癌症疾病的患者。